Antigen-Presenting Synthetic Surfaces for Reproducible T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapy methods for cancer treatment lack reproducibility and characterizability in activating tumor-targeting cytotoxic T lymphocytes using dendritic cells.
Innovation Solution
Development of antigen-presenting surfaces with specific molecular ligands, including MHC Class I molecules and TCR co-activating molecules, to enhance T cell activation, with controlled ratios and densities of ligands for improved T cell specificity and activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cells are used to activate T lymphocytes for immunotherapy, then T cell activation can be achieved, but the process lacks reproducibility and characterizability
Solution Approach 1:
The patent creates a synthetic surface that copies the essential antigen-presenting functions of dendritic cells. Instead of using complex biological dendritic cells, the invention uses a simplified synthetic surface displaying MHC molecules and co-stimulatory ligands, achieving reproducible T cell activation without the variability inherent in biological systems.
Solution Approach 2:
The patent controls the density and ratio of MHC molecules to co-stimulatory ligands on the synthetic surface. By optimizing these parameters (MHC:ligand ratios from 1:1 to 1:10), the invention achieves reproducible and characterizable T cell activation, transforming an unpredictable biological process into a controlled system with defined parameters.
2Measurement precision
If specific molecular ligands are incorporated into the antigen-presenting surface to improve T cell activation, then T cell specificity increases, but the device complexity increases
Solution Approach 1:
The patent divides the antigen-presenting surface into distinct functional regions with specific molecular ligands. MHC molecules are separated from co-stimulatory ligands (CD28, CD2, CD27, CD137), allowing each component to be independently controlled and optimized for specific T cell activation pathways.
Solution Approach 2:
The synthetic surface incorporates multiple types of co-stimulatory ligands (CD28, CD2, CD27, CD137) that can activate different T cell pathways. This multi-functional approach allows a single surface design to achieve comprehensive T cell activation with high specificity while maintaining a manageable structural framework.
3Productivity
If controlled ratios of TCR co-activating molecules to adjunct TCR activating molecules are used, then T cell activation efficiency improves, but manufacturing precision requirements increase
Solution Approach 1:
The patent defines specific MHC to co-stimulatory ligand ratio ranges (1:1 to 1:10) that optimize T cell activation. By establishing these parameter ranges, the invention balances activation efficiency with manufacturing feasibility, allowing controlled variation while maintaining therapeutic effectiveness.
Solution Approach 2:
The synthetic surface is pre-functionalized with MHC molecules and co-stimulatory ligands in controlled ratios before T cell exposure. This preliminary preparation ensures consistent activation conditions without requiring precise real-time adjustments during the immunotherapy process, simplifying manufacturing while maintaining efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described surfaces effectively produce a population of antigen-specific T cells, enhancing their activation and cytotoxicity against cancer cells, providing a more reproducible and characterizable approach for immunotherapy.
Implementation Method 1
each primary activating molecular ligand comprises a major histocompatibility complex (MHC) Class I molecule and an antigenic peptide associated thereto and is configured to bind to a T cell receptor (TCR) of the T cell
Implementation Method 2
the TCR co-activating molecule comprises a CD28 binding protein or a fragment thereof which retains binding ability with CD28
Implementation Method 3
the adjunct TCR activating molecule comprises a CD2 binding protein or a fragment thereof which retains binding ability with CD2
Data Source
Figure 1A
Figure 1B~1C
Figure 2A~2B
AI summary
In biosciences and related fields, it can be useful to modify surfaces of apparatuses, devices, and materials that contact biomaterials such as biomolecules and biological micro-objects. Described herein are surface modifying and surface functionalizing reagents, preparation thereof, and methods for modifying surfaces to activate T Lymphocytes.